Solid Biosciences Welcomes Industry Expert Dr. Martin Freed To Its Board Of Directors
“I want to thank Gilad for his many significant contributions to Solid and service to the Duchenne muscular dystrophy community,” said
Dr. Zarur continued, “Dr. Freed’s breadth of hands-on experience in helping companies advance innovative products through clinical development and approval is impressive. He brings this expertise to Solid, and we are delighted to welcome him to our Board.”
“Gilad was the first to support our vision that we can and should aggressively pursue a plan to bring meaningful therapies to all patients with Duchenne muscular dystrophy,” said
Dr.
Dr. Freed has held senior leadership positions with various biopharmaceutical companies, most recently as Co-Founder and Chief Medical Officer of
Dr. Freed performed his internal medicine residency at
About Solid Biosciences
Solid Biosciences is a life science company focused solely on finding meaningful therapies for Duchenne muscular dystrophy (DMD). Founded by those touched by the disease, Solid is a center of excellence for DMD, bringing together experts in science, technology and care to drive forward a portfolio of candidates that have life-changing potential. Currently, Solid is progressing programs across four scientific platforms: Corrective Therapies, Disease-Modifying Therapies, Disease Understanding and Assistive Devices. For more information, please visit www.solidbio.com.
Forward-looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with Solid’s ability to obtain and maintain necessary approvals from the FDA and other regulatory authorities and investigational review boards at clinical trial sites; enroll patients in its clinical trials; continue to advance SGT-001 in clinical development; replicate in later clinical trials positive results found in preclinical studies and earlier stages of clinical development; advance the development of its product candidates under the timelines it anticipates in current and future clinical trials; obtain, maintain or protect intellectual property rights related to its product candidates; compete successfully with other companies that are seeking to develop DMD treatments and gene therapies; manage expenses; and raise the substantial additional capital needed to achieve its business objectives. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties and other important factors, in the Company’s most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date hereof and should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.
Contact:
Kate Niazi-Sai
+1 617-337-4680
media@solidbio.com
investors@solidbio.com
Source: Solid Biosciences Inc.